Abstract
This study links ARID1A loss with enhanced glycolysis in lung cancer and demonstrates the preclinical efficacy of BET inhibitor therapy as a strategy to combat tumor growth.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have